Lupin

Lupin Net Debt / EBITDA

The Net Debt to EBITDA of Lupin (LUPIN.NS) as of Nov 10, 2026 is 0.12. In the previous year, Net Debt to EBITDA was 0.08 — a change of 39.25% (higher).

Net Debt / EBITDA

0.12

YoY

39.25%

Last updated:

Net Debt to EBITDA of Lupin is 2025 0.12 . Net Debt to EBITDA of Lupin was 2024 0.08 . It decreases by 39.25% higher compared to the previous year.

The Lupin Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
1.73 INR
Jan 1, 2019
0.93 INR
Jan 1, 2020
0.74 INR
Jan 1, 2021
0.17 INR
Jan 1, 2022
0.35 INR
Jan 1, 2023
1.41 INR
Jan 1, 2024
0.08 INR
Jan 1, 2025
0.12 INR
The Lupin Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.12+39.25%
0.08-94.01%
1.41+301.86%
0.35+105.97%
0.17-76.98%
0.74-20.13%
0.93-46.48%
1.73+160.66%
0.67-34.36%
1.01-473.24%
-0.27+4,647.63%
-0.01-101.74%
0.33-65.54%
0.96+72.23%
0.56-39.01%
0.91-44.90%
1.65+9.73%
1.51+597.79%
0.22—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lupin Stock analysis

What does Lupin do? Lupin Limited is an Indian pharmaceutical company specializing in generics and novel therapies. It was founded in 1968 by Dr. Desh Bandhu Gupta and has experienced rapid growth, becoming one of the leading companies in the global pharmaceutical market. The company's business model involves manufacturing and marketing generics and novel therapies for the treatment of various diseases such as cancer, diabetes, cardiovascular diseases, and respiratory diseases. Lupin operates worldwide with a wide range of partners to distribute its products in over 100 countries. The company is involved in various divisions including generics, novel therapies, biosimilars, and inhalation products. Lupin's generics division encompasses a wide range of products such as antibiotics, antidepressants, antihypertensives, and many other categories. Its novel therapies include innovative products for the treatment of diabetes, cancer, multiple sclerosis, and other chronic diseases. Lupin is also involved in the development of biosimilars, which are imitation biopharmaceuticals manufactured using living organisms. Lastly, the company offers inhalation products for the treatment of respiratory diseases such as asthma and COPD. Lupin has built an impressive product pipeline over the years, having submitted over 174 ANDA applications (for the approval of new generics) to the US FDA and introduced more than 80 new products in the Indian market. It has also established an innovative research and development center that focuses on the discovery of new molecules and the development of new therapeutic approaches. Another important feature of Lupin is its commitment to quality and sustainability. The company has received numerous awards for its product quality and environmental initiatives. In 2019, Lupin received the Sustainable Business Award from CNBC TV18. Overall, Lupin Limited is a successful and fast-growing company specializing in generics and novel therapies. It has a wide range of products and an impressive pipeline, and operates globally. Due to its commitment to quality and sustainability, Lupin Limited has also built a strong reputation among its customers and partners. Lupin is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lupin stock

Net Debt to EBITDA of Lupin is 0.12 in 2025.

Net Debt to EBITDA of Lupin changed from 0.08 to 0.12, representing a 39.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Lupin since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Lupin with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Lupin

All Key Metrics — Lupin